Cartesian Therapeutics, Inc. (RNAC)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$6.18-3.59%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Cartesian Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	324,400
EPS	—	-1.085
Annual ending 2026-12-31
Revenue	—	419,143
EPS	—	-3.004
Annual ending 2027-12-31
Revenue	—	333,333
EPS	—	-4.159

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Release topline data from Phase 3 AURORA trial in Q1 2027	The company plans to share key trial data in early 2027.	Intact	Data release delayed past Q1 2027	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Complete Phase 3 trial for Descartes-08 by mid-2027	Cartesian aims to finish its Phase 3 trial by mid-2027.	Intact	Trial completion delayed beyond mid-2027	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2 and a recent 2026-09 press release. Management expects topline data from the Phase 3 AURORA trial in Q1 2027 and plans a BLA filing by mid-2027. The trial enrollment is progressing, and the company remains on track, indicating delivery consistent with stated plans. Delivery assessment Oct 24, 2026
Execute announced share buyback program	It has started a share buyback program.	Improving	No buyback activity by end 2026	Buyback announced May 2026 vs target by end 2026 May 2026 filing reports entry into a Loan Agreement and announcement of a share buyback program. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$458,857	4 / 6
2026-07-25	Unavailable	$401,500	1 / 8
2026-07-26	Unavailable	$401,500	1 / 8
2026-07-27	Unavailable	$458,857	4 / 6
2026-07-28	Unavailable	$458,857	4 / 6
2026-07-29	Unavailable	$458,857	4 / 6
2026-07-30	Unavailable	$458,857	4 / 6
2026-07-31	Unavailable	$458,857	4 / 6
2026-08-01	Unavailable	$458,857	4 / 6
2026-08-02	Unavailable	$401,500	1 / 8
2026-08-03	Unavailable	$401,500	1 / 8
2026-08-04	Unavailable	$401,500	1 / 8
2026-08-05	Unavailable	$458,857	4 / 6
2026-08-06	Unavailable	$401,500	1 / 8
2026-08-08	Unavailable	$458,860	1 / 7
2026-08-09	Unavailable	$458,860	1 / 7
2026-08-10	Unavailable	$458,857	4 / 6
2026-08-12	Unavailable	$458,857	4 / 6
2026-08-13	Unavailable	$285,710	1 / 7
2026-08-14	Unavailable	$458,857	4 / 6
2026-08-15	Unavailable	$458,857	4 / 6
2026-08-16	Unavailable	$458,857	4 / 5
2026-08-17	Unavailable	$458,857	4 / 5
2026-08-18	Unavailable	$458,857	4 / 6
2026-08-19	Unavailable	$458,857	4 / 6
2026-08-20	Unavailable	$285,714	4 / 5
2026-08-21	Unavailable	$285,714	4 / 5
2026-08-22	Unavailable	$285,714	4 / 5
2026-08-23	Unavailable	$285,714	4 / 5
2026-08-24	Unavailable	$285,714	4 / 5
2026-08-25	Unavailable	$285,714	4 / 5
2026-08-26	Unavailable	$285,714	4 / 5
2026-08-27	Unavailable	$285,714	4 / 5
2026-08-28	Unavailable	$285,714	4 / 5
2026-08-29	Unavailable	$285,714	4 / 5
2026-08-30	Unavailable	$285,714	4 / 5
2026-08-31	Unavailable	$285,714	4 / 5
2026-09-01	Unavailable	$285,714	4 / 5
2026-09-02	Unavailable	$285,714	4 / 5
2026-09-03	Unavailable	$285,714	4 / 5
2026-09-04	Unavailable	$285,714	4 / 5
2026-09-05	Unavailable	$285,714	4 / 5
2026-09-06	Unavailable	$285,714	4 / 5
2026-09-07	Unavailable	$285,714	4 / 5
2026-09-08	Unavailable	$285,714	4 / 5
2026-09-09	Unavailable	$285,714	4 / 5
2026-09-10	Unavailable	$285,714	4 / 5
2026-09-11	Unavailable	$285,714	4 / 5
2026-09-12	Unavailable	$285,714	4 / 5
2026-09-13	Unavailable	$285,714	4 / 5
2026-09-14	Unavailable	$285,714	4 / 5
2026-09-15	Unavailable	$285,714	4 / 5
2026-09-16	Unavailable	$285,714	4 / 5
2026-09-17	Unavailable	$333,333	4 / 5
2026-09-18	Unavailable	$333,333	4 / 5
2026-09-19	Unavailable	$333,333	4 / 5
2026-09-20	Unavailable	$333,333	4 / 5
2026-09-21	Unavailable	$333,333	4 / 5
2026-09-22	Unavailable	$333,333	4 / 5
2026-09-23	Unavailable	$333,333	4 / 5
2026-09-24	Unavailable	$333,333	4 / 5
2026-09-25	Unavailable	$333,333	4 / 5
2026-09-26	Unavailable	$333,333	4 / 5
2026-09-27	Unavailable	$333,333	4 / 5
2026-09-28	Unavailable	$333,333	4 / 5
2026-09-29	Unavailable	$333,333	4 / 5
2026-09-30	Unavailable	$333,333	4 / 5
2026-10-01	Unavailable	$333,333	4 / 5
2026-10-02	Unavailable	$333,333	4 / 5
2026-10-03	Unavailable	$333,333	4 / 5
2026-10-04	Unavailable	$333,333	4 / 5
2026-10-05	Unavailable	$333,333	4 / 5
2026-10-06	Unavailable	$333,333	4 / 5
2026-10-07	Unavailable	$333,333	4 / 5
2026-10-08	Unavailable	$333,333	4 / 5
2026-10-09	Unavailable	$333,333	4 / 5
2026-10-10	Unavailable	$333,333	4 / 5
2026-10-11	Unavailable	$333,333	4 / 5
2026-10-12	Unavailable	$333,333	4 / 5
2026-10-13	Unavailable	$333,333	4 / 5
2026-10-14	Unavailable	$333,333	4 / 5
2026-10-15	Unavailable	$333,333	4 / 5
2026-10-16	Unavailable	$333,333	4 / 5
2026-10-17	Unavailable	$333,333	4 / 5
2026-10-18	Unavailable	$333,333	4 / 5
2026-10-19	Unavailable	$333,333	4 / 5
2026-10-20	Unavailable	$333,333	4 / 5
2026-10-21	Unavailable	$333,333	4 / 5
2026-10-22	Unavailable	$333,333	4 / 5
2026-10-23	Unavailable	$333,333	4 / 5
2026-10-24	Unavailable	$333,333	4 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	8	1
2026-06-01	8	0
2026-07-01	8	0
2026-08-01	8	0
2026-09-01	8	0
2026-10-01	7	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades2 maintains

Recent actions · Sep 25–Oct 24 · 2 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Release topline data from Phase 3 AURORA trial in Q1 2027Qualitative condition
Complete Phase 3 trial for Descartes-08 by mid-2027Qualitative condition

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.3%Typical daily move · historical

Downside history

-42.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Cartesian Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotechnology investment, not a profitable compounder. The long-term thesis is intact, though the recent signal has shifted from mildly favorable to mixed and near-term earnings risk is elevated.

What's priced into Cartesian Therapeutics, Inc.

RNAC is valued at a premium to peers, with a low-confidence valuation model and expectations tied to future clinical optionality, meaning potential value from pipeline programs. The evidence labels that premium unjustified, but does not show that the full combination of expensive valuation, weak results, and turbulence is priced in.

What the fundamentals likely do

Near-term results may remain erratic, with an elevated risk of an earnings miss despite a reported earnings beat in August. Over the multi-year view, management says the Phase 3 AURORA trial remains on track, with topline data expected in Q1 2027 and a planned filing by mid-2027; TRITON and HELIOS updates are expected in the first half of 2027. Progress against these milestones is mixed overall, and the evidence does not establish commercial performance.

What Cartesian Therapeutics, Inc. hinges on

The central swing factor is whether AURORA delivers useful data on the stated timeline, alongside progress in TRITON and HELIOS. A guidance cut or further weakening in jobs data would add pressure, while continued strong results and higher guidance from healthcare bellwethers could support sector momentum.